Dr. Moliterno has disclosed that she is on the advisory board for Incyte Corporation. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Editor's Note: The NCCN Guidelines for MPNs were recently released and are available at NCCN.org. They will also be published in the December 2016 issue of JNCCN.
RollisonDEHowlanderNSmithMT. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood2008;112:45–52.
PassamontiFRumiEPungolinoE. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med2004;117:755–761.
TefferiARumiEFinazziG. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia2013;27:1874–1881.
FinazziGCarusoVMarchioliRECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood2005;105:2664–2670.
Alvarez-LarránABellosilloBMartínez-AvilésL. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol2009;146:504–509.
BerkPDWassermanLRFruchtmanSMGoldbergJD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: WassermanLRBerkPDBerlinNI eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: WB Saunders; 1995:166–194.
BerkPDGoldbergJDSilversteinMN. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med1981;304:441–447.
BerkPDGoldbergJDDonovanPB. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol1986;23:132–143.
StreiffMBSmithBSpivakJL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood2002;99:1144–1149.
BaxterEJScottLMCampbellPJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet2005;365:1054–1061.
JamesCUgoVLe CouedicJP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature2005;434:1144–1148.
LevineRLWadleighMCoolsJ. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell2005;7:387–397.
SteinBLOhSBerenzonD. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol2015;33:3953–3960.
VardimanJWThieleJArberDA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937–951.
KiladjianJJCassinatBChevretS. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood2008;112:3065–3072.
VerstovsekSPassamontiFRambaldiA. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer2014;120:513–520.
SquizzatoARomualdiEPassamontiFMiddeldorpS. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev2013:CD006503.
SteinBLGotlibJArcasoyM. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw2015;13:424–434.
Di NisioMBarbuiTDi GennaroLEuropean Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol2007;136:249–259.
TartagliaAPGoldbergJDBerkPDWassermanLR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol1986;23:172–176.
NajeanYRainJD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood1997;90:3370–3377.
CortelazzoSFinazziGRuggeriM. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med1995;332:1132–1136.
HarrisonCNCampbellPJBuckGUnited Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med2005;353:33–45.
GisslingerHGoticMHolowieckiJANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood2013;121:1720–1728.
MascarenhasJMesaRPrchalJHoffmanR. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica2014;99:945–949.
CampbellPJMacLeanCBeerPA. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood2012;120:1409–1401.